PMS13 EXPERIMENTAL STUDY OF TOPICAL TREATMENT OF RHEUMATOID ARTHRITIS WITH TNF-Α ANTAGONIST

Abstract

To observe the clinical efficacy of intra-articular injection of recombinant human tumor necrosis factor receptor type II antibody fusion protein in patients with rheumatoid arthritis (RA). (1)Case selection: 60 patients with RA were randomly divided into experimental group and control group. (2) In the experimental group, 25 mg of recombinant human tumor necrosis factor receptor-antibody fusion protein was injected into each joint; in the control group, the same dose of the same drug was injected subcutaneously each time. (3) The content of MMP-3 was determined by enzyme-linked immunosorbent assay (ELISA). Clinical indicators were collected: ESR, CRP, PLT, and joint color Doppler ultrasonography. Synovial thickness and fluid depth of knee joint. After 2 weeks of treatment, ESR, CRP and PLT in the experimental group were lower than those in the control group, with no significant difference (P > 0.05). The synovial thickness and liquid depth in the experimental group were significantly lower than those in the control group (P < 0.05). After 2 weeks of treatment, the content of MMP-3 in the joint fluid of both groups decreased significantly, compared with the control group (P < 0.05). Intra-articular injection of recombinant human tumor necrosis factor receptor-antibody fusion protein can significantly reduce synovial thickness, fluid depth, and the content of MMP-3 in synovial fluid, which is an effective method for the treatment of rheumatoid arthritis.